Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

References

Page 1

	Year	Citations
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, CA A Cancer Journal for Clinicians	2018	86.6K
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, New England Journal of Medicine	2016	9.8K
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie R. Brahmer, Karen L. Reckamp, Paul Baas, New England Journal of Medicine	2015	8.4K
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn, Shukui Qin, Masafumi Ikeda, New England Journal of Medicine	2020	6.8K
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim, The Lancet Pembrolizumab Versus DocetaxelOncologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapy	2015	6.4K
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon, Naiyer A. Rizvi, Rina Hui, New England Journal of Medicine	2015	6.1K
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, New England Journal of Medicine	2018	3.3K
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database Ramaswamy Govindan, Nathan Page, Daniel Morgensztern, Journal of Clinical Oncology	2006	1.8K
Improved Survival with Bevacizumab in Advanced Cervical Cancer Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, New England Journal of Medicine	2014	1.5K

Page 1